Centrient Pharmaceuticals
Climate Impact & Sustainability Data (2018-01 to 2019-12, 2020-2021, 2022-2023, 2023)
Reporting Period: 2018-01 to 2019-12
Environmental Metrics
ESG Focus Areas
- Antimicrobial Resistance (AMR)
- Water and environment
- Improving access
- Science and Innovation
- Climate and energy
- Responsible procurement
Environmental Achievements
- Hit the vast majority of environmental targets for 2020
- Semi-synthetic penicillin (SSP) API product range meets PNEC discharge targets set by the AMR Industry Alliance two years ahead of schedule
- Received EcoVadis Gold sustainability rating (top 4% of companies in the “Manufacture of basic pharmaceutical products and pharmaceutical preparations” industry)
- Reduced carbon footprint by up to 65% compared with the traditional chemical process for PureActives®
Social Achievements
- Expanded CSR approach in India and Mexico with positive impact on health and education
- Appropriate Antibiotic Use project in China rolled out across 70 hospitals
- Launched several fitness-driven initiatives for employees (health check-up camps, fitness bikes, fitness dance sessions, yoga day, Happy Garden initiative)
- Launched the TOR scheme for older employees in the Netherlands to improve work-life balance
- Launched Centrient Young Professionals Network
Governance Achievements
- Introduced PSCI principles and PSCI audit programme in own operations and full supply chain
- First AMR supplier assessment survey done
- Developed a Sustainability Assessment Tool (SAT)
- Implemented Sustainability Assessment through the Self-Assessment Questionnaire (SAQ)
- Adopted Guidelines for Disciplinary Sanctions
Climate Goals & Targets
- Not disclosed
- Achieve 43% overall energy efficiency improvement by 2020
- Realise a 49% CO2 efficiency improvement by 2020
- Achieve full PNEC-compliant supply chain by 2021
- Complete sustainability assessments of Category C suppliers by 2022
- Complete sustainability assessments for Category B suppliers by 2024
Environmental Challenges
- Some 2020 objectives will go unrealised
- Climate change and AMR posing a growing threat
- Drug shortages due to fragile supply chain and price competition
- Increased public and governmental scrutiny on environmental impact
- Increased stakeholder scrutiny on AMR from antibiotic pollution
Mitigation Strategies
- Developing the next stage of our Sustainability Strategy (Roadmap for 2025 and beyond)
- Working with customers, suppliers and other partners to drive industry awareness and action on critical sustainability issues
- Engaging with stakeholders to raise awareness of supply chain vulnerability
- Expanding supply footprint and ensuring product registrations to reach patients globally
- Implementing the AMR Industry Alliance’s Common Antibiotic Manufacturing Framework
- Achieving PNEC compliance for SSPs
- Developing environmental KPIs for 2021-2025
- Implementing corrective and preventive measures to address key findings after audits
Supply Chain Management
Supplier Audits: 73 audits in 2018 and 2019
Responsible Procurement
- Supplier Code of Conduct
- PSCI principles
- Sustainability Assessment Tool (SAT)
- Self-Assessment Questionnaire (SAQ)
Climate-Related Risks & Opportunities
Reporting Standards
Frameworks Used: GRI
Certifications: ISO 14001 (except China)
UN Sustainable Development Goals
- 3
- 6
- 12
- 13
The report details how initiatives contribute to these goals.
Sustainable Products & Innovation
- PureActives®
Awards & Recognition
- 2018 GSK Environmental Sustainability Suppliers Award
Reporting Period: 2020-2021
Environmental Metrics
ESG Focus Areas
- Minimising environmental impact
- Improving human health and social impact
- Acting responsibly
Environmental Achievements
- 14% carbon emission reduction (against 2015 baseline)
- 10% solid waste reduction (against 2015 baseline)
- 50% improvement in relative CO2 efficiency
- 45% energy reduction
- 25% water reduction
- 100% PNEC compliant across the entire supply chain of oral antibiotics
- Integrated sustainability assessment into project management and capital expenditure approval processes
- Launched ESG Ambition 2021–2030
Social Achievements
- Donated nearly 60,000 face masks and installed two oxygen plants in hospitals in India during COVID-19
- Reached 100,000 people in 100 hospitals throughout China with an awareness campaign on AMR
- Installed 280 solar-powered streetlights in four villages near Toansa plant
- Introduced new Centrient Code of Conduct and Business Partner Code of Conduct
- Introduced SpeakUp platform for reporting breaches of the Code of Conduct
- Established Human Rights Committee
- Renovated two schools in Toansa, India
Governance Achievements
- Increased female representation on Executive Committee and Board of Directors
- Introduced a refined purpose, vision and strategy for the company
Climate Goals & Targets
- Net zero emissions (target year not explicitly stated, but implied by 2030 goals)
- 50% reduction in carbon emission intensity by 2030
- 90% of waste repurposed by 2030
- Source 50% renewable electricity by 2030
- 5% reduction in water consumption intensity by 2030
- Sites and suppliers compliant with AMR IA Common Manufacturing Framework and PNEC target values by 2030
- R&D projects pass Sustainability assessment (2025)
- Increasing access of our life-saving antibiotics to 2 billion patients by 2030
- 50,000+ lives touched by Centrient global community programme annually by 2030
- 75% of top suppliers meet sustainability standards (2025)
- 35% reduction in carbon emission intensity by 2025
- High level of employee engagement - in top 10% for our industry (2025)
- 50% gender balance in senior management roles (2025)
- Certified human and labour rights compliance in our operations (2024)
- Several diverse members at Board level (2025)
- 100% of eligible employees committed to Code of Conduct (2024)
Environmental Challenges
- COVID-19 impact on operations and supply chains
- Drug shortages due to fragile supply chain
- Antimicrobial resistance (AMR)
- Reducing scope 3 emissions
Mitigation Strategies
- Established local and global task forces to address COVID-19 challenges
- Implemented multi-supplier strategy to secure supply chain
- Developed comprehensive approach to eliminate AMR from wastewater treatment operations
- Developed an internal AMR survey for assessing AMR risks in the antibiotic supply chain
- Working on aligning climate targets with science-based targets (SBTs)
Supply Chain Management
Supplier Audits: 13 PSCI sustainability audits conducted in 2021, with 5 more planned for 2022. 73 suppliers passed ESG assessments.
Responsible Procurement
- Business Partner Code of Conduct
- Sustainability self-assessment questionnaire (SAQ)
- PSCI principles
- AMR survey
Climate-Related Risks & Opportunities
Reporting Standards
Frameworks Used: GRI Standards: Core option
Certifications: ISO 14001
UN Sustainable Development Goals
- 3
- 6
- 12
- 13
Centrient links its material topics and efforts to SDGs 3 (Good Health and Well-being), 6 (Clean Water and Sanitation), 12 (Responsible Consumption and Production), and 13 (Climate Action).
Sustainable Products & Innovation
- PureActives® range of APIs and FDFs
Awards & Recognition
- EcoVadis Gold Sustainability rating (2020 and 2021)
Reporting Period: 2022-2023
Environmental Metrics
ESG Focus Areas
- Antimicrobial resistance
- Water and environment
- Improving access
- Science and Innovation
- Climate and energy
- Waste management
- Responsible procurement
- Human capital development
- Human rights
- Patient safety
- Community impact
Environmental Achievements
- 5% carbon emissions reduction compared to 2015 baseline
- 10% energy intensity reduction compared to 2021 baseline
- 25% electricity sourced from renewable sources
- 97% of waste repurposed compared to 2015 baseline
- 10% water consumption reduction compared to 2021 baseline
- 100% compliance with PNEC limits
- Santa Perpetua site (Spain) certified under AMR Industry Alliance scheme
Social Achievements
- Established a Mobile Healthcare Unit in Toansa, India, benefitting more than 1,200 people in 2023
- Reached 2,500 people impacted by the 2023 Toansa flooding by distributing essential medicines and hygiene kits
- Impacted more than 45,000 lives around the world through CSR programme
- 97% of eligible employees completed Code of Conduct certification (2023)
- Completed Human Rights Impact assessment
- Developed and established a Sustainable Sourcing Policy
- Improved gender balance at senior level, with 30% of senior management roles held by women
- Launched a Centrient Community Action strategy and framework
- Facilitated 1.5 billion patient treatments globally (2023)
Governance Achievements
- Maintained Gold rating for EcoVadis Supplier Assessment in 2022 and 2023
- Completed the Human Rights Impact assessment
- Developed and established a Sustainable Sourcing Policy
Climate Goals & Targets
- Not disclosed
- 50% reduction in carbon emission intensity by 2030
- 90% of waste repurposed by 2030
- 50% renewable electricity by 2030
- Maximise water recycling and look for options to reduce groundwater use by 2030
- Sites and suppliers compliant with AMR IA Common Manufacturing Framework and PNEC targets by 2030
- Increasing access of life-saving antibiotics to 2 billion patients by 2030
- 50,000+ lives touched by Centrient’s global community programme annually by 2030
- 35% reduction in carbon emission intensity by 2025
- 5% reduction in water consumption intensity by 2025
- R&D projects pass Sustainability assessment by 2025
- High level of employee engagement - in top 10% for our industry by 2025
- 50% gender balance in senior management roles by 2025
- 75% of top suppliers meet sustainability standards by 2025
Environmental Challenges
- Supply chain disruptions
- Global shortages of essential medicines
- Growing demand for medicines
- Antimicrobial resistance (AMR)
Mitigation Strategies
- Multi-supplier strategy to avoid dependence on single suppliers
- Backward-integrated production for better supply chain control
- Capacity increase projects at Toansa (India), Yushu (China), and Ramos Arizpe (Mexico)
- Sustainable Antibiotics programme to reduce antibiotic emission and prevent AMR
- 100% compliance with PNEC target values for all wastewater streams
- Collaboration with AMR Industry Alliance and BSI for AMR certification
Supply Chain Management
Supplier Audits: 10 key suppliers assessed in 2023; 6 PSCI sustainability audits conducted in 2022-2023
Responsible Procurement
- Business Partner Code of Conduct (BPCoC)
- Sustainability self-assessment questionnaire (SAQ)
- PSCI principles
- AMR survey
Climate-Related Risks & Opportunities
Physical Risks
- Not disclosed
Transition Risks
- Not disclosed
Opportunities
- Development of energy-efficient products
Reporting Standards
Frameworks Used: GRI Core Option, UN Sustainable Development Goals (SDGs)
Certifications: ISO 14001
Third-party Assurance: Not disclosed
UN Sustainable Development Goals
- 3
- 6
- 12
- 13
Centrient's initiatives contribute to these goals through improving access to medicines, responsible water and waste management, sustainable energy use, and climate action.
Sustainable Products & Innovation
- PureActives® range of enzymatically produced antibiotics
Awards & Recognition
- Gold Sustainability Rating from EcoVadis (2022 and 2023)
Reporting Period: 2023
Environmental Metrics
ESG Focus Areas
- Environmental
- Social
- Governance
- Antimicrobial Resistance (AMR)
Environmental Achievements
- 97% of waste repurposed (compared to 2021 baseline)
- 10% water consumption reduction (compared to 2021 baseline)
- 25% electricity sourced from renewable sources (compared to 2015 baseline)
- 46.2% absolute reduction in scope 1 and 2 greenhouse gas emissions by 2031 (target)
- 27.5% absolute reduction in scope 3 greenhouse gas emissions by 2031 (target)
Social Achievements
- Facilitated 1.5 billion patient treatments globally (2023)
- 97% of all eligible employees completed Code of Conduct certification (2023)
- Launched a Centrient Community Action strategy and framework
- Established a Mobile Healthcare Unit in Toansa, India, benefitting more than 1,200 people in 2023
- Impacted more than 45,000 lives around the world through CSR programs and activities
- Reached 2,500 people impacted by the 2023 Toansa flooding by distributing essential medicines and hygiene kits
Governance Achievements
- Maintained 100% compliance with PNEC limits
- Certified Spain site under new AMR IA scheme
- Introduced shadow carbon pricing evaluation for key investments
- Climate targets validated by the Science Based Targets initiative (SBTi)
- Reported data to the Carbon Disclosure Project for the first time in July 2023
- Developed and established a Sustainable Sourcing Policy
- Maintained EcoVadis Gold rating in 2022 and 2023
Climate Goals & Targets
- 46.2% absolute reduction in scope 1 and 2 GHG emissions by 2031
- 27.5% absolute reduction in scope 3 GHG emissions by 2031
- 50,000+ lives touched by Centrient global community programme annually by 2030
- Source 50% renewable electricity by 2030
- Increasing access of our lifesaving antibiotics to 2 billion patients by 2030
- 90% of waste repurposed and landfill only if no viable alternative available by 2030
- 5% reduction in water consumption intensity by 2030
- R&D projects pass Sustainability assessment (2025)
- Sites and suppliers compliant with AMR IA Common Manufacturing Framework and Predicted No-Effect Concentration targets
- High level of employee engagement - in top 10% for our industry (2025)
- 50% gender balance in senior management roles (2025)
- 100% of eligible employees committed to Code of Conduct (2024)
- Certified human and labour rights compliance in our operations (2024)
- 75% of top suppliers meet sustainability standards (2025)
Supply Chain Management
Responsible Procurement
- Sustainable Sourcing Policy
Climate-Related Risks & Opportunities
Sustainable Products & Innovation
- PureActives (enzymatic platform)